In addition to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection
itself, an increase in the incidence of antimicrobial resistance poses collateral damage to the …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus,
is the main pathogenic agent of the rapidly spreading pneumonia called coronavirus …

The monkeypox outbreak has emerged in 13 countries and increased alarmingly since the
first confirmed case in the UK on May 7, 2022 [1]. The WHO has reported 28 suspected and …

Bacterial or virus co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have been reported in many studies, however, the knowledge on Aspergillus co …

The COVID-19 pandemic has generated an overuse of antimicrobials in critically ill patients.
Acinetobacter baumannii frequently causes nosocomial infections, particularly in intensive …

The emergence of the monkeypox outbreak in early 2022 has posed a new global health
threat. As of July 8, 2022, 9069 laboratory-confirmed cases have been reported, and most of …

Purpose The aim of the study was to report clinical features, contributing factors and
outcome of patients with coronavirus disease 2019 (COVID‐19)‐associated mucormycosis …

Severe COVID-19 disease is associated with an increase in pro-inflammatory markers, such
as IL-1, IL-6, and tumor necrosis alpha, less CD4 interferon-gamma expression, and fewer …

Monkeypox is a rare viral infection, endemic in many central and western African countries.
The last international outbreak of monkeypox reported outside Africa occurred back in 2003 …

Abstract Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a
complicated challenge, especially among patients with severe disease. In recent studies …